Oruka Therapeutics, Inc. (ORKA) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -634.0%, revenue growth 130.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $16.63M |
| Revenue (TTM) | $0.0B |
| Net Margin | -634.0% |
| Return on Equity | -11.9% |
| Operating Margin (TTM) | -699.0% |
| Current Ratio | 38.51 |
| Interest Coverage | -60.0 |
| Revenue Growth (YoY) | 130.7% |
| FCF Growth (YoY) | 145.0% |
| Price / Book | 5.49 |
| Price / Sales | 275.68 |
| FCF Yield | -1.4% |
| Altman Z-Score | 164.02 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
ORKA overview · ORKA earnings · ORKA KPIs · ORKA documents · ORKA ownership · ORKA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.